Beyond FDG: Serial 68 Ga-FAPI PET/CT for Staging and Treatment Response Assessment in Metastatic Pleomorphic Lobular Breast Cancer.

Clin Nucl MedMay 15, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)

Khulood Al Riyami, Anjali Jain, Asiya Al Busaidi et al.

✦ AI-curated · Sources linked

Case in brief

A patient with recurrent metastatic pleomorphic lobular breast cancer underwent baseline 68 Ga-FAPI PET/CT, which revealed extensive regional and distant disease that was underestimated by 18 F-FDG PET/CT. Following the initiation of olaparib, serial FAPI PET/CT scans showed a marked response, indicating near complete resolution of the disease.

Diagnostic / clinical pearl

68 Ga-FAPI PET/CT may provide superior sensitivity for detecting metastatic disease in lobular breast cancer compared to traditional 18 F-FDG PET/CT.

Why it matters

This case underscores the potential of 68 Ga-FAPI PET/CT in assessing treatment response, which could influence management strategies for patients with lobular breast cancer.

Source

PubMed · PMID 42149908

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.